Siddhartha Mitra

3.9k total citations · 1 hit paper
24 papers, 2.6k citations indexed

About

Siddhartha Mitra is a scholar working on Molecular Biology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, Siddhartha Mitra has authored 24 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Genetics and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Siddhartha Mitra's work include Chronic Lymphocytic Leukemia Research (9 papers), Mitochondrial Function and Pathology (5 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Siddhartha Mitra is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Mitochondrial Function and Pathology (5 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Siddhartha Mitra collaborates with scholars based in United States, France and United Kingdom. Siddhartha Mitra's co-authors include Steven Finkbeiner, Montserrat Arrasate, Erik S. Schweitzer, Mark R. Segal, Andrey S. Tsvetkov, Jeannie Chin, Carol Peebles, Vikram R. Rao, Jason Miller and Richard W. Tsien and has published in prestigious journals such as Nature, Cell and Journal of Biological Chemistry.

In The Last Decade

Siddhartha Mitra

24 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

2004 1.5k citations Montserrat Arrasate, Siddhartha Mitra et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Siddhartha Mitra United States	14	1.6k	1.5k	563	417	320	24	2.6k
Hiroko Yano United States	23	1.5k 1.0×	1.3k 0.9×	229 0.4×	409 1.0×	204 0.6×	56	2.8k
Mohamed H. Farah United States	21	1.5k 0.9×	1.0k 0.7×	587 1.0×	368 0.9×	904 2.8×	38	3.3k
Georg Haase France	22	1.4k 0.9×	681 0.5×	684 1.2×	328 0.8×	245 0.8×	28	2.4k
Albena Jordanova Belgium	32	1.9k 1.1×	1.7k 1.1×	518 0.9×	570 1.4×	296 0.9×	87	3.6k
Bernhard K. Mueller Germany	26	1.6k 1.0×	2.4k 1.6×	252 0.4×	745 1.8×	232 0.7×	38	3.7k
Eva Hedlund Sweden	32	2.6k 1.6×	1.1k 0.7×	716 1.3×	122 0.3×	353 1.1×	58	3.8k
Ignacio Muñoz-Sanjuán United States	29	2.4k 1.4×	1.2k 0.8×	470 0.8×	267 0.6×	208 0.7×	82	3.3k
Annalisa Buffo Italy	31	1.9k 1.2×	1.6k 1.1×	280 0.5×	254 0.6×	323 1.0×	72	4.3k
Abdellatif Benraiss United States	28	1.8k 1.1×	1.7k 1.1×	307 0.5×	195 0.5×	413 1.3×	45	3.7k
Cédric Raoul France	28	1.3k 0.8×	688 0.5×	1.2k 2.1×	232 0.6×	374 1.2×	70	2.7k

Countries citing papers authored by Siddhartha Mitra

Since Specialization

Citations

This map shows the geographic impact of Siddhartha Mitra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siddhartha Mitra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siddhartha Mitra more than expected).

Fields of papers citing papers by Siddhartha Mitra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siddhartha Mitra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siddhartha Mitra. The network helps show where Siddhartha Mitra may publish in the future.

Co-authorship network of co-authors of Siddhartha Mitra

This figure shows the co-authorship network connecting the top 25 collaborators of Siddhartha Mitra. A scholar is included among the top collaborators of Siddhartha Mitra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siddhartha Mitra. Siddhartha Mitra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Picard, Daniel, Viktoria Marquardt, Jasmin Bartl, et al.. (2025). An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT). Pharmacological Research. 213. 107660–107660. 2 indexed citations

Wainberg, Zev A., Peter C. Enzinger, Yoon‐Koo Kang, et al.. (2021). Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. Journal of Clinical Oncology. 39(3_suppl). 160–160. 63 indexed citations

Catenacci, Daniel V.T., Yoon‐Koo Kang, Anwaar Saeed, et al.. (2021). FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. Journal of Clinical Oncology. 39(15_suppl). 4010–4010. 31 indexed citations

Danilov, Alexey V., Charles Herbaux, Harriet S. Walter, et al.. (2020). Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(12). 2810–2818. 47 indexed citations

Tejani, Mohamedtaki Abdulaziz, Eric Cheung, Peter D. Eisenberg, et al.. (2019). Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).. Journal of Clinical Oncology. 37(4_suppl). 91–91. 8 indexed citations

Danilov, Alexey V., Charles Herbaux, Martin J.S. Dyer, et al.. (2018). Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 3135–3135. 1 indexed citations

Gopal, Ajay K., Michelle A. Fanale, Craig H. Moskowitz, et al.. (2017). Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma. Annals of Oncology. 28(5). 1057–1063. 40 indexed citations

Nectow, Alexander R., Marc Schneeberger, Hongxing Zhang, et al.. (2017). Identification of a Brainstem Circuit Controlling Feeding. Cell. 170(3). 429–442.e11. 114 indexed citations

Jürgensmeier, Juliane M., Hoa Truong, Lianqing Zheng, et al.. (2017). Abstract 4082: Time- and exposure-dependent pharmacodynamic changes induced by the BTK inhibitor GS-4059 in healthy subjects. Cancer Research. 77(13_Supplement). 4082–4082. 1 indexed citations

10.

Walter, Harriet S., Sandrine Jayne, Simon Rule, et al.. (2016). Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood. 128(22). 3233–3233. 1 indexed citations

11.

Salles, Gilles, Franck Morschhauser, Bruce D. Cheson, et al.. (2016). Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. Blood. 128(22). 2961–2961. 1 indexed citations

12.

Sharman, Jeffrey P., Andrei R. Shustov, Mitchell R. Smith, et al.. (2016). Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway. Blood. 128(22). 3225–3225. 4 indexed citations

13.

Sharman, Jeff P., Andrei R. Shustov, Mitchell R. Smith, et al.. (2015). Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. Blood. 126(23). 1744–1744. 3 indexed citations

14.

Peters‐Libeu, Clare, Jason Miller, Earl Rutenber, et al.. (2012). Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact Structure. Journal of Molecular Biology. 421(4-5). 587–600. 46 indexed citations

15.

Mitra, Ananya, Siddhartha Mitra, & Richard W. Tsien. (2011). Heterogeneous reallocation of presynaptic efficacy in recurrent excitatory circuits adapting to inactivity. Nature Neuroscience. 15(2). 250–257. 70 indexed citations

16.

Miller, Jason, Montserrat Arrasate, Benjamin A. Shaby, et al.. (2010). Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis. Journal of Neuroscience. 30(31). 10541–10550. 127 indexed citations

17.

Mitra, Siddhartha, Andrey S. Tsvetkov, & Steven Finkbeiner. (2009). Protein turnover and inclusion body formation. Autophagy. 5(7). 1037–1038. 51 indexed citations

18.

Mitra, Siddhartha, Andrey S. Tsvetkov, & Steven Finkbeiner. (2008). Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease. Journal of Biological Chemistry. 284(7). 4398–4403. 83 indexed citations

19.

Rao, Vikram R., et al.. (2006). AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc. Nature Neuroscience. 9(7). 887–895. 157 indexed citations

20.

Arrasate, Montserrat, Siddhartha Mitra, Erik S. Schweitzer, Mark R. Segal, & Steven Finkbeiner. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 431(7010). 805–810. 1541 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact